Paper
CAR-T Cell Therapy for Follicular Lymphomas
Published Jan 1, 2024 · Ugo Testa, F. D'Alo', E. Pelosi
Mediterranean Journal of Hematology and Infectious Diseases
2
Citations
0
Influential Citations
Abstract
Follicular lymphoma is the second most diagnosed lymphoma in Western Europe. Significant advancements have considerably improved the survival of FL patients. However, 10–20% of these patients are refractory to standard treatments, and most of them will relapse. The treatment of follicular lymphoma patients with multiply relapsed or refractory disease represents an area of high-unmet needing new treatments with stronger efficacy. Chimeric antigen receptor (CAR)-T cell therapy targeting B-cell antigens, such as CD19 or CD20, is emerging as an efficacious treatment for R/R follicular lymphoma patients, particularly for those with early relapse and refractory to alkylating agents and to anti-CD20 monoclonal antibodies, resulting in a high rate of durable responses in a high proportion of patients.
CAR-T cell therapy is an effective treatment for follicular lymphoma patients with relapsed or refractory disease, providing high rates of durable responses in a high proportion of patients.
Full text analysis coming soon...